QIAGEN and Applied Biosystems settle all disput...

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




 Rotor-Gene(TM) Q now fully "Licensed Real-Time Thermal Cycler" for
         all molecular research and diagnostic applications

Venlo, The Netherlands, January 22, 2008 --- Corbett, QIAGEN (NASDAQ:
QGEN; Frankfurt, Prime Standard: QIA), ltf Labortechnik GmbH & Co.
KG, and Applied Biosystems, LLC, part of Life Technologies
Corporation (Nasdaq: LIFE) today announced a settlement of their
disputes concerning infringement by Corbett's Rotor-Gene(TM)
Real-Time PCR-Cyclers and Applied Biosystems' Real-Time Thermal
Cycler Instrument patents. Applied Biosystems had filed an
infringement lawsuit against Corbett in Germany and Corbett later
filed a declaratory judgment lawsuit in California. Further, Corbett
and ltf Labortechnik filed an intervention in opposition proceedings
before the European Patent Office. QIAGEN acquired Corbett, an
Australian instrumentation manufacturing company, in July 2008.

In connection  with  the  settlement, Corbett  has  entered  into  an
agreement with  Applied  Biosystems to  take  a license  to  -certain
technology relating  to Corbett's  Real-Time PCR-Instrumentation  and
its use.  The license  covers all  fields including  research-related
fields, applied fields and  the fields of human  and animal in  vitro
diagnostics.

Financial terms of the settlement and related license agreement  were
not disclosed. These  agreements fully resolve  all pending  disputes
between Corbett, QIAGEN, ltf Labortechnik, and Applied Biosystems.

"This Real-Time  Thermal  Cycler  license agreement  for  all  fields
including  human  in  vitro  diagnostics  expands  our  existing  PCR
intellectual property estate which is truly unique in the  industry",
said Peer  Schatz, CEO  of QIAGEN.  "The Rotor-Gene(TM)  Q  Real-time
Thermal Cycler  technology  adds high  performance,  proprietary  PCR
detection technology to QIAGEN.  This addition extends our  molecular
testing solution portfolio  and puts  QIAGEN in a  position to  offer
sample and assay technology solutions spanning from sample to result.
This settlement  agreement  allows us  to  place our  full  focus  on
delivering the most advanced technology solutions to our customers in
molecular diagnostics, applied testing, pharma and academic research.
We are pleased that our Rotor-Gene Q(TM) Real-Time Thermal Cycler can
be marketed with the additional  mark of a fully 'Licensed  Real-Time
Thermal Cycler' for all fields."


About Thermal Cyclers and PCR
Thermal cyclers  are the  key instruments  for performing  polymerase
chain reactions  (PCR).  PCR,  used in  life  science  and  molecular
diagnostics, is a process in which  a segment of a nucleic acid  (DNA
or RNA) is copied or "amplified" so that the nucleic acid can be more
readily analyzed. In  real-time PCR,  the amplified  DNA is  detected
during, rather than at  the end of, the  PCR process, a feature  that
facilitates greater  accuracy  in important  applications,  including
pathogen detection, gene expression quantization and genotyping.


About QIAGEN
QIAGEN N.V., a Netherlands holding  company, is the leading  provider
of sample and  assay technologies.  Sample technologies  are used  to
isolate and process  DNA, RNA, and  proteins from biological  samples
such as blood  or tissue. Assay  technologies are used  to make  such
isolated bio-molecules visible. QIAGEN has developed and markets more
than 500 consumable products as well as automated solutions for  such
consumables.  The  company   provides  its   products  to   molecular
diagnostics laboratories,  academic researchers,  pharmaceutical  and
biotechnology companies, and applied  testing customers for  purposes
such as forensics, animal or food testing, and pharmaceutical process
control. QIAGEN's assay technologies include what is considered to be
the broadest panel of molecular diagnostic tests available worldwide.
This  panel   includes  the   only   FDA-approved  test   for   human
Papillomavirus (HPV), the  primary cause of  cervical cancer.  QIAGEN
employs more than 3.000 people  in more than 30 locations  worldwide.
Further    information    about    QIAGEN    can    be    found    at


http://www.qiagen.com/.

Statements contained in  this release that  are not historical  facts
are  forward-looking  statements,  including  statements  about   our
products, markets, strategy  and operating  results. Such  statements
are  based   on  current   expectations   that  involve   risks   and
uncertainties including, but not  limited to, those associated  with:
management of growth and international operations (including currency
fluctuations and logistics),  variability of  our operating  results,
commercial development  of our  markets (including  applied  testing,
clinical  and  academic  research,  proteomics,  women's   health/HPV
testing and molecular diagnostics), our relationships with customers,
suppliers and strategic partners, competition, changes in technology,
fluctuations  in   demand,  regulatory   requirements,   identifying,
developing and producing integrated products differentiated from  our
competitors'  products,  market  acceptance  of  our  products,   and
integration of  acquired  technologies and  businesses.  For  further
information, refer to our filings with the SEC, including our  latest
Form 20-F.  Information in  this release  is as  of the  date of  the
release, and we undertake no  duty to update this information  unless
required by law.

                                # # #

Contacts:


Dr. Solveigh Mähler                      Dr. Thomas Theuringer
Director Investor Relations              Associate  Director   Public
QIAGEN N.V.                              Relations
[phone]                        QIAGEN GmbH
email:                                   [phone]
[e-mail]              email:
                                         [e-mail]
Albert F. Fleury
Investor Relations North America
QIAGEN N.V.
[phone]
email: [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;